Salem Investment Counselors Inc Ocuphire Pharma, Inc. Transaction History
Salem Investment Counselors Inc
- $3.24 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding OCUP
# of Institutions
44Shares Held
2.54MCall Options Held
2KPut Options Held
2K-
Vanguard Group Inc Valley Forge, PA992KShares$1.34 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA266KShares$358,9020.0% of portfolio
-
Richmond Brothers, Inc. Jackson, MI191KShares$258,2600.6% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX164KShares$221,0500.01% of portfolio
-
Black Rock Inc. New York, NY107KShares$144,3620.0% of portfolio
About Ocuphire Pharma, Inc.
- Ticker OCUP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,579,800
- Market Cap $27.8M
- Description
- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...